| |||||
| |||||
| Hello Nature readers, | |||||
 | |||||
| Normally hidden to the naked eye by the Sun's glare, the corona will be visible to millions of people during a total eclipse on 8 April. (Alan Dyer/VW Pics/UIG via Getty) | |||||
Watch for corona during Monday's eclipseOn 8 April, researchers will get an unprecedented view of the Sun's outer wispy atmosphere: the corona. The solar eclipse visible in parts of North America will coincide with a solar maximum — a period of extreme activity that occurs every 11 years. One research team will chase the eclipse from a jet, adding 90 more seconds of observation time to the maximum of 4 minutes and 30 seconds seen by observers on the ground. One question they're hoping to answer: why the corona is so much hotter than the solar surface. That, says solar physicist James Klimchuk, is like walking away from a campfire — but finding that instead of cooling down, you get warmer. Nature | 6 min read | |||||
Share your eclipse pics with Nature📸 We'd love to see your best photos of the eclipse or related views from the day. Please upload them here. Don't forget to use eye protection and put safety first! Our favourite images will be featured in this Briefing and we'll send our top snapper a money-can't-buy Nature tote bag and pin badge. 😎 | |||||
Diabetes drug slows Parkinson's diseaseA diabetes drug called lixisenatide has shown promise in slowing the progression of Parkinson's disease. Lixisenatide is in the family of GLP-1 receptor agonists, such as Ozempic, that have made headlines as weight-loss drugs. In the latest clinical trial, lixisenatide was given to people with mild to moderate Parkinson's who were already receiving a standard treatment for the condition. After a year they saw no worsening of their symptoms, unlike a control group whose condition did worsen. Further work is needed to reduce the drug's side effects, such as nausea and vomiting, and to determine whether its benefits last. "We're all cautious. There's a long history of trying different things in Parkinson's that ultimately didn't work," says neurologist David Standaert. Nature | 4 min readReference: The New England Journal of Medicine paper | |||||
Gates Foundation endorses preprintsThe Bill & Melinda Gates Foundation, one of the world's top biomedical research funders, will from next year require grant holders to make their research publicly available as preprints, which are not peer reviewed. It will also no longer pay article-processing charges (APCs) to publishers in order to secure open access, in which the peer-reviewed version of the paper is free to read. The change follows criticism that APCs create inequities because of the costs they push onto researchers and funders. "We've become convinced that this money could be better spent elsewhere," said a Gates representative. Nature | 7 min read | |||||
Question of the weekThis week, we learnt that some scientists are turning to Reddit as their social media network of choice. Its data are free for non-commercial researchers and academics. And its communities offer a space to network with other scientists or share research with the public. If you're a working scientist, what do you think about using Reddit? | |||||
| |||||
What Rwanda is teaching us about genocideThis week marks 30 years since the start of the 1994 genocide in Rwanda, in which members of the Hutu ethnic group killed an estimated 800,000 people from Tutsi communities. The event is now one of the most researched of its kind. These studies are difficult, not least because because the genocide almost wiped out Rwanda's academic community. But efforts, especially by local researchers, are helping to inform responses to other violent crises and longer-term approaches to healing. Sociologist Assumpta Mugiraneza is leading challenging work that gathers testimonies from the genocide — and of the rich lives people had before the atrocity. To think about genocide, she says, "we must dare to seek humanity where humanity has been denied". Nature | 17 min read | |||||
 | |||||
ACCESS NATURE AND 54 OTHER NATURE JOURNALS Nature+ is our most affordable 30-day subscription, giving you online access to a wide range of specialist Nature Portfolio journals, including Nature. Nature+ is for personal use and is suitable for students. | |||||
Futures: These monkeys make no senseTwo future academics — a rat and a raven — ponder the fate of past primates in the latest short story for Nature's Futures series. Nature | 6 min read | |||||
Five best science books this weekAndrew Robinson's pick of the top five science books to read this week includes an account of women working in nature and a thoughtful history of how our unequal society deals with epidemics. Nature | 4 min read | |||||
Scientist parents battle imposter syndromeWhen Brazilian biologist Fernanda Staniscuaski returned from parental leave, her grant applications started to be rejected because she "was not producing as much as my peers". "Maybe I was never meant to be in science," she recalls thinking. As the founder of the Parent in Science movement, she is now lobbying for greater acceptance of career breaks. As a first step, the Brazilian Ministry of Education has created a working group to develop a national policy for mothers in academia. "That was huge," Staniscuaski says. Nature Careers Working Scientist podcast | 20 min listen | |||||
 | |||||
Quote of the day"Fate played a miserable trick — it gave us the best fossil early on."When the remains of the Australopithecus afarensis nicknamed 'Lucy' were discovered in 1974, we never could have predicted how rare such finds would be, says paleoanthropologist Bernard Wood. Nevertheless, the accumulated evidence of even older hominins has challenged Lucy's status as 'mother of us all'. (Science | 14 min read) | |||||
| | |||||
| |||||
| | |||||
| Want more? Update your preferences to sign up to our other free Nature Briefing newsletters:
| |||||
| |||||
| You received this newsletter because you subscribed with the email address: manojdole1.Lens@blogger.com Please add briefing@nature.com to your address book. Enjoying this newsletter? You can use this form to recommend it to a friend or colleague — thank you! Had enough? To unsubscribe from this Briefing, but keep receiving your other Nature Briefing newsletters, please update your subscription preferences. To stop all Nature Briefing emails forever, click here to remove your personal data from our system. Fancy a bit of a read? View our privacy policy. Forwarded by a friend? Get the Briefing straight to your inbox: subscribe for free. Want to master time management, protect your mental health and brush up on your skills? Sign up for our free short e-mail series for working scientists, Back to the lab. Get more from Nature: Register for free on nature.com to sign up for other newsletters specific to your field and email alerts from Nature Portfolio journals. Would you like to read the Briefing in other languages? 关注Nature Portfolio官方微信订阅号，每周二为您推送Nature Briefing精选中文内容——自然每周简报。 Nature Portfolio | The Springer Nature Campus, 4 Crinan Street, London, N1 9XW, United Kingdom Nature Portfolio, part of Springer Nature. |
What matters in science | View this email in your browser Monday 11 December 2023 Hello Nature readers, Today, we gaze at what might be the largest known protein, learn about the first global deal on limiting emissions from food production and discover how publishing pressures create unusually prolific authors. A structure prediction for a massive protein discovered by computational biologist Jacob West-Roberts and his colleagues. (West-Roberts, J. et al./bioRxiv ) Not...
Comments
Post a Comment